Celltrion to Buy Additional 500,000 Treasury Shares...Total Purchase Reaches 250 Billion KRW

Scheduled On-Exchange Purchase Worth 71.25 Billion KRW by August 18
"Judging Stock Undervalued... Enhancing Shareholder Value"

[Asia Economy Reporter Lee Gwan-joo] Celltrion announced that it held a board meeting on the 18th and decided to purchase additional treasury shares to stabilize its stock price and enhance shareholder value.

Celltrion plans to acquire a total of 500,000 treasury shares this time, with an estimated acquisition amount of approximately 71.25 billion KRW, through on-market purchases from July 19 to August 18.

Previously, Celltrion decided to purchase a total of 1,055,883 treasury shares, including 547,946 shares in January and 507,937 shares in February, and completed the acquisition. With this additional treasury share purchase, the total treasury shares Celltrion has decided to acquire this year amount to 1,555,883 shares, worth about 250 billion KRW.

Regarding this additional treasury share purchase, Celltrion explained that it made the decision because it continues to maintain solid growth through its biopharmaceutical and chemical pharmaceutical businesses and believes that the current stock price level is still undervalued.

A Celltrion official stated, “With confidence in business growth and to enhance shareholder value, we are conducting the third treasury share purchase this year,” adding, “Celltrion will continue to strengthen its global business competitiveness through reinforcing its product pipeline and securing future growth engines, and will do its best to preserve corporate value and enhance shareholder value.”